A hair loss regime consisting of finasteride, minoxidil and microneedling that was started 4 months ago with minimal side effects reported. The user also uses Nizoral once a week.
The conversation is about a 23-year-old who started treating their hair loss with daily oral dutasteride (0.5mg), oral minoxidil (2.5mg), topical RU58841 (80mg), and weekly microneedling at 1.5mm after seeing others' success stories. Significant improvements have been noted, and there is optimism for even better results in the next 6 months.
Using a combination of topical finasteride, minoxidil, caffeine and dermaroller treatments to help with hair loss, while discussing the potential results and other options.
User discusses 4.5 months of using 0.5 DUT & 5 mg Oral Min for hair loss. They share progress pictures and discuss styling options and shedding experiences.
The conversation discusses which vitamins to take alongside 0.5mg finasteride for hair loss, with suggestions including a multivitamin, iron, zinc, B12, vitamin D, Nutrafol, collagen, vitamin C, saw palmetto, and magnesium. Nutrafol is noted for its benefits but also criticized for containing too much biotin.
User reports progress in hair loss treatment using finasteride, topical minoxidil, dutasteride, RU58841, and oral minoxidil. Positive results include thicker, darker hair and improved hairline.
This conversation discusses the potential benefits of using oral minoxidil and finasteride to treat hair loss, with some users sharing their own experiences in taking the medications. Others express concerns about the safety of these treatments.
A user sharing their progress after using Fin, Minoxidil, keto diet, and microneedling for two months to attempt to regrow hair on bald temples. Other users replied with advice and support.
User experienced significant hair regrowth after 4 months using Dutasteride, Minoxidil, castor oil, rosemary spray, Ketoconazole, and microneedling. Others praised the impressive results and attributed them mainly to Dutasteride.
Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.
User started fin/min/niz at 23, switched to Dut at 24, and has been on treatments for 7 years. Despite occasional doubts, hair improved and user advises sticking with treatments.
Hair loss is often misunderstood by those not affected, leading to frustration for those who research treatments like Minoxidil, finasteride, and hair transplants. Many people offer well-meaning but uninformed advice, while those knowledgeable about hair loss focus on proven treatments.
A user who has started to go bald and decided to try wearing a hair piece, discussing the experience of doing so and sharing tips for maintenance. The conversation includes discussion about confidence in relation to wearing a wig or hair piece, as well as advice on getting it cut and attached professionally.
Fluridil degrades androgenreceptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.
Researching and developing an effective local antagonist to block the androgenreceptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
Finasteride and dutasteride are discussed for hair loss, with concerns about their effects on neurosteroids and potential side effects like depression. Alternatives like topical estrogen and lifestyle changes are considered, with varying opinions on mental health and hair regrowth.
Bicalutamide blocks androgenreceptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.
The conversation discusses the effectiveness of anti-androgens for hair loss, with a preference for topical treatments like RU58841 over oral options due to better scalp concentration and fewer side effects. Topical finasteride at 0.1% may provide some results, especially when combined with a topical androgenreceptor antagonist like RU58841.
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.
The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.
RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.